Nasdaq

Microbot Medical’s Self-Cleaning Shunt (SCS™) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro Laboratory Study

HINGHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Having successfully concluded an independent in-vitro laboratory study and published the positive results earlier this year, the operational ...
Business Insider

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed ...

Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30 ...
Nasdaq

Microbot Medical Inc. Achieves Key Milestones in Preparation for LIBERTY® Endovascular Robotic System Launch

Microbot Medical Inc. announces key milestones, including FDA 510(k) submission, in preparation for LIBERTY's commercial launch in 2025. Microbot Medical Inc. announced the successful completion of ...